NASDAQ:GRTX - Galera Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.75
  • Forecasted Upside: 790.15 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.32
▲ +0.03 (2.33%)

This chart shows the closing price for GRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTX

Analyst Price Target is $11.75
▲ +790.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $11.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 790.15% upside from the last price of $1.32.

This chart shows the closing price for GRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Galera Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/30/2022HC WainwrightReiterated RatingBuy$10.00Low
5/27/2022Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
12/20/2021CitigroupBoost Price TargetBuy$11.00 ➝ $20.00High
12/15/2021HC WainwrightUpgradeNeutral ➝ Buy$10.00High
12/14/2021BTIG ResearchUpgradeNeutral ➝ Buy$15.00High
12/14/2021Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
10/21/2021CitigroupLower Price TargetBuy$21.00 ➝ $11.00Medium
10/20/2021HC WainwrightDowngradeBuy ➝ NeutralMedium
10/19/2021Bank of AmericaDowngradeBuy ➝ Underperform$17.00 ➝ $2.00N/A
10/19/2021BTIG ResearchDowngradeBuy ➝ NeutralN/A
9/26/2021BTIG ResearchReiterated RatingBuy$30.00High
9/24/2021HC WainwrightReiterated RatingBuy$15.00High
9/9/2021HC WainwrightReiterated RatingBuy$15.00Low
6/29/2021HC WainwrightReiterated RatingBuy$15.00Medium
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$15.00High
12/16/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform$9.00 ➝ $15.00Medium
12/7/2020HC WainwrightInitiated CoverageBuy$15.00High
11/11/2020Credit Suisse GroupBoost Price TargetNeutral$8.00 ➝ $9.00Low
10/28/2020Smith Barney CitigroupBoost Price Target$18.00 ➝ $21.00High
7/29/2020Credit Suisse GroupLower Price TargetNeutral$14.00 ➝ $8.00Low
12/2/2019BTIG ResearchInitiated CoverageBuy$30.00High
12/2/2019Credit Suisse GroupInitiated CoverageNeutral$14.00High
12/2/2019CitigroupInitiated CoverageBuy$20.00High
12/2/2019Bank of AmericaInitiated CoverageBuy$15.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

-0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Galera Therapeutics logo
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.32
Low: $1.31
High: $1.32

50 Day Range

MA: $1.55
Low: $1.24
High: $1.87

52 Week Range

Now: $1.32
Low: $1.15
High: $10.79

Volume

350 shs

Average Volume

90,829 shs

Market Capitalization

$35.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Galera Therapeutics?

The following Wall Street research analysts have issued reports on Galera Therapeutics in the last year: Bank of America Co., BTIG Research, Citigroup Inc., and HC Wainwright.
View the latest analyst ratings for GRTX.

What is the current price target for Galera Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Galera Therapeutics in the last year. Their average twelve-month price target is $11.75, suggesting a possible upside of 810.9%.
View the latest price targets for GRTX.

What is the current consensus analyst rating for Galera Therapeutics?

Galera Therapeutics currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRTX will outperform the market and that investors should add to their positions of Galera Therapeutics.
View the latest ratings for GRTX.

How do I contact Galera Therapeutics' investor relations team?

Galera Therapeutics' physical mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The company's listed phone number is 610-725-1500 and its investor relations email address is [email protected] The official website for Galera Therapeutics is www.galeratx.com. Learn More about contacing Galera Therapeutics investor relations.